Exploring Entera Bio Ltd. (ENTX) Investor Profile: Who’s Buying and Why?

Are you curious about who's investing in Entera Bio Ltd. (ENTX) and why? As of December 31, 2024, a total of 19 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 7,528,596 shares. Major players like Knoll Capital Management, LLC hold a significant position with 5,881,879 shares, while others such as Schonfeld Strategic Advisors LLC and Parkman Healthcare Partners LLC also have notable stakes. With Entera Bio's cash position at $21 million as of March 2025 and a runway extending into Q3 2026, covering critical milestones such as the planned EB613 Phase 3 study, understanding the investor profile becomes crucial. Let's delve into the details of who is betting on Entera Bio and the potential reasons behind their investment decisions.

Entera Bio Ltd. (ENTX) Who Invests in [Company Name] and Why?

Understanding the investor profile of Entera Bio Ltd. (ENTX) provides valuable insights into market sentiment and potential future stock performance. Examining the different types of investors, their motivations, and typical strategies can help current and prospective shareholders make informed decisions. Here's a breakdown of ENTX's investor landscape:

Entera Bio's shareholder base comprises a mix of retail investors, institutional investors, and insiders. As of February 2025, the ownership structure is as follows:

• Retail Investors: Represent a significant portion of ENTX's ownership. Retail investors hold approximately 59.80% of Entera Bio's shares.
• Institutional Investors: These entities hold a notable percentage of ENTX, with institutional ownership at 20.39%.
• Insiders: Company insiders, including officers and directors, own 19.81% of the company.

The presence of each investor type influences the stock's trading dynamics. For example, large institutional holdings can provide stability, while retail interest can drive short-term volatility.

Several institutional investors have significant positions in Entera Bio. These include:

• Knoll Capital Management LLC: Stands out as the largest shareholder. As of February 18, 2025, Knoll Capital Management LLC holds 5,881,879 shares, representing about 15.03% of the company, valued at approximately $12.47 million.
• Schonfeld Strategic Advisors LLC: Holds 632,311 shares, accounting for 1.72% ownership.
• Parkman Healthcare Partners LLC: Owns 413,732 shares, representing 1.12% of the company.
• Northern Trust Corp: Holds 212,483 shares, accounting for 0.58% ownership.
• Perigon Wealth Management LLC: Holds 145,843 shares, representing approximately 0.40% ownership.

Investors are drawn to Entera Bio for several key reasons:

• Growth Prospects: Entera Bio is a clinical-stage company focused on developing oral peptide and protein replacement therapies. Its pipeline includes EB613 for osteoporosis and EB612 for hypoparathyroidism, addressing significant unmet medical needs. The company is preparing to initiate a Phase 3 registrational study for EB613, pursuant to the FDA's qualification of a quantitative BMD endpoint.
• Technology Platform: Entera Bio leverages its proprietary N-Tab™ technology platform for oral delivery of macromolecules. This platform stabilizes peptides in the gastrointestinal tract and promotes their absorption into the bloodstream.
• Collaboration Agreements: Strategic partnerships, such as the collaboration with OPKO Health to advance oral GLP-1/Glucagon tablet candidates for obesity and metabolic disorders, enhance Entera Bio's potential and appeal to investors.
• Financial Health: As of March 28, 2025, Entera Bio had approximately $21 million in cash and cash equivalents, attributed to direct investments from existing and new institutional shareholders and its partner, OPKO. This financial stability supports ongoing clinical trials and research activities.

Investors in Entera Bio may employ various strategies depending on their investment goals and risk tolerance:

• Long-Term Holding: Many institutional investors, such as Knoll Capital Management, may adopt a long-term holding strategy. This approach focuses on the company's potential to generate significant returns as its oral peptide therapies advance through clinical trials and regulatory approvals.
• Short-Term Trading: Given the volatility often associated with biotech stocks, some investors may engage in short-term trading strategies to capitalize on price fluctuations.
• Value Investing: Some investors may view Entera Bio as undervalued, considering its innovative technology and pipeline potential. These investors may focus on the intrinsic value of the company and expect the market to recognize its true worth over time.

As of April 17, 2025, the share price was $1.79 per share. On April 22, 2024, the share price was $2.05 per share, reflecting a 12.68% decline over the year. This fluctuation highlights the risks associated with investing in clinical-stage biotech companies.

Institutional ownership in Entera Bio has seen some changes. According to Fintel, there are 19 institutional owners, with a -5.00% change MRQ. The total institutional shares (Long) are 7,528,596, representing 16.58% (excluding 13D/G), with a 40.94% change MRQ.

Explore more about Entera Bio Ltd.’s background and mission: Entera Bio Ltd. (ENTX): History, Ownership, Mission, How It Works & Makes Money

Understanding who invests in Entera Bio and why can offer valuable insights for potential investors. The mix of retail, institutional, and insider ownership, coupled with the company's promising pipeline and technology, creates a dynamic investment landscape.

Entera Bio Ltd. (ENTX) Institutional Ownership and Major Shareholders of Entera Bio Ltd. (ENTX)

Understanding the institutional ownership of Entera Bio Ltd. (ENTX) can provide valuable insights into the company's stability, investor confidence, and potential stock performance. Institutional investors, such as mutual funds, hedge funds, and pension funds, often have significant resources and conduct extensive research before investing. Their positions can influence market perception and stock price movements.

As of the latest available data, several major institutional investors hold significant stakes in Entera Bio Ltd. (ENTX). While specific holdings can change frequently, some of the top institutional investors may include:

• Vanguard Group: Known for its large index funds and ETFs, Vanguard often holds shares in many publicly traded companies.
• BlackRock Fund Advisors: As one of the world's largest asset managers, BlackRock typically has positions in a wide array of stocks.
• State Street Corp: Another major player in the asset management industry, State Street could hold a notable percentage of ENTX shares.
• RTW Retail Trading LLC: RTW Retail Trading LLC is the largest shareholder, with 2,681,819 shares as of December 31, 2024.

Changes in institutional ownership can signal shifts in sentiment towards Entera Bio Ltd. (ENTX). For example, if several major institutional investors increase their positions, it could indicate a positive outlook on the company's future prospects. Conversely, a decrease in institutional holdings might suggest concerns about the company's performance or industry trends.

The role of institutional investors in Entera Bio Ltd. (ENTX)'s stock price and strategy is substantial. Large institutional investors can drive trading volume and influence price volatility. Their investment decisions often reflect in-depth analyses of the company's financials, pipeline progress, and market opportunities. The presence of strong institutional backing can also enhance a company's credibility and attract further investment.

For further insights into Entera Bio Ltd. (ENTX)'s financial health, explore: Breaking Down Entera Bio Ltd. (ENTX) Financial Health: Key Insights for Investors

Here is a table summarizing potential institutional ownership data (Note: Actual data may vary and should be verified through official filings):

It's important for investors to monitor these changes and understand the motivations behind institutional investment decisions, as they can provide valuable context for assessing Entera Bio Ltd. (ENTX) as an investment.

Entera Bio Ltd. (ENTX) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Entera Bio Ltd. (ENTX) is crucial for gauging market sentiment and potential stock movements. Key investors can significantly influence company decisions and stock performance through their holdings and strategic moves.

While specific, real-time major shareholder data and their direct influence on Entera Bio Ltd. (ENTX) require up-to-the-minute financial data sources, examining general trends and influential investors in similar biotech companies can provide valuable insights. Institutional investors, venture capital firms specializing in biotech, and strategic corporate partners often play pivotal roles.

Institutional investors, such as mutual funds, hedge funds, and pension funds, typically hold significant stakes in biotech companies. Their investment decisions are driven by factors like the company's pipeline, clinical trial results, and market potential. Large institutional ownership can provide stability but also introduce volatility if these investors decide to liquidate their positions.

Venture capital firms frequently invest in early-stage biotech companies, providing crucial funding for research and development. These firms often have board representation and actively participate in strategic decisions. Their expertise and network can be invaluable for a company's growth, but their investment horizon is typically shorter-term, aiming for an exit through an acquisition or IPO.

Strategic corporate partners, such as pharmaceutical companies, may invest in or collaborate with biotech firms to gain access to innovative technologies or drug candidates. These partnerships can provide financial resources and validation of the company's science. The influence of these partners can be substantial, shaping the company's strategic direction and R&D priorities.

Recent moves by key investors, such as increasing or decreasing their positions, can signal confidence or concern about the company's prospects. Activist investors may also emerge, advocating for specific changes in corporate governance or strategy to unlock value.

To gain a deeper understanding of Entera Bio Ltd. (ENTX)'s financial standing, explore Breaking Down Entera Bio Ltd. (ENTX) Financial Health: Key Insights for Investors.

For illustrative purposes, consider the following hypothetical examples of key investors and their potential impact:

• Vanguard Group: A large mutual fund known for its long-term investment approach. A significant stake held by Vanguard could indicate confidence in Entera Bio Ltd. (ENTX)'s long-term potential.
• RA Capital Management: A healthcare-focused investment firm with a track record of successful biotech investments. RA Capital's involvement could signal strong potential in Entera Bio Ltd. (ENTX)'s pipeline.
• Bayer AG: A major pharmaceutical company partnering with Entera Bio Ltd. (ENTX) on a specific drug development program. This partnership would not only provide funding but also validate Entera Bio Ltd. (ENTX)'s technology.

The influence of these investors can manifest in various ways:

• Board Representation: Major investors often have seats on the board of directors, allowing them to directly influence company decisions.
• Shareholder Votes: Large shareholders have a significant say in important corporate matters, such as mergers and acquisitions or executive compensation.
• Market Perception: The presence of well-respected investors can enhance the company's credibility and attract other investors.

Keeping track of these investors' moves, analyzing their motivations, and understanding their potential impact is essential for anyone investing in Entera Bio Ltd. (ENTX).

Here is a sample table outlining potential investors and their possible impact on Entera Bio Ltd. (ENTX):

Disclaimer: This is a hypothetical analysis based on general investment trends in the biotech industry and does not represent actual investors in Entera Bio Ltd. (ENTX) as of April 2025. For accurate and up-to-date information, consult reliable financial news sources and regulatory filings.

Entera Bio Ltd. (ENTX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Entera Bio Ltd. (ENTX) is crucial for assessing the company's current standing and future prospects. Recent market behavior and analyst perspectives provide valuable insights into how major shareholders influence the stock.

Investor sentiment toward Entera Bio Ltd. (ENTX) can be gauged by observing the behavior of its major shareholders. Positive sentiment is often reflected in increased buying activity, while negative sentiment may lead to selling pressure. Monitoring these activities helps to understand the overall confidence in the company's performance and strategic direction.

Recent market reactions to changes in ownership or large investor moves can significantly impact the stock price of Entera Bio Ltd. (ENTX). For instance, a substantial purchase by a well-known institutional investor might drive the stock price up, signaling confidence in the company's potential. Conversely, a large sell-off could lead to a price decline, indicating concerns about the company's prospects.

Here are some factors influencing investor sentiment:

• Clinical Trial Results: Positive outcomes from clinical trials typically boost investor confidence.
• Regulatory Approvals: Approvals from regulatory bodies like the FDA can significantly enhance the company's market value.
• Partnerships and Collaborations: Strategic alliances can signal growth and stability, attracting investors.
• Financial Performance: Revenue growth and profitability are key indicators of a company's health and can drive investor interest.

Analysts' perspectives on Entera Bio Ltd. (ENTX) often highlight the potential impact of key investors on the company's future. These insights can include:

• Growth Prospects: Assessments of the company's ability to expand its market presence.
• Financial Stability: Evaluations of the company's financial health and sustainability.
• Technological Advancements: Analysis of the company's innovative capabilities and their potential impact.

For example, analysts might comment on how a major investor's long-term vision aligns with Entera Bio Ltd. (ENTX)'s strategic goals, or how their expertise could benefit the company's development and commercialization efforts. These perspectives can influence both current and potential investors.

The following table provides a hypothetical overview of recent market reactions based on investor activities:

Understanding the history, ownership structure, mission, and revenue model of Entera Bio Ltd. (ENTX) can provide additional context for evaluating investor behavior and market dynamics. More information can be found at: Entera Bio Ltd. (ENTX): History, Ownership, Mission, How It Works & Makes Money.